Building LCB's own
clinical stage pipeline
about us
Dedicated to revolutionizing new drug discovery and development
Vision 2030
Global Top ADC company by year 2030
2020
2025
2030
2020
Platform
- Linker / PBD Toxins
- Conjugation
How we do
- monospecific antibodies
- cytotoxin payload
Business model
- Early-stage candidate out-licensing at preclinical stage
2025
Platform
- Novel MoA Toxins
- I/O Payloads
How we do
- ADCs with bispecific antibodies
- Novel ADC payloads that span multiple modes of action
- ADC in combination with small molecules for Immuno-Oncology
Business model
- Value inflection through clinical development of LCB's own pipelines up to phase 1/2
2030
Platform
- Novel Ab/Ligand
- Non-cancer linkers
How we do
- Revolutionary ADC therapies that span the entire ADC spectrum beyond cancer - Immunotherapy, infectious disease, etc.
Business model
- Entering into late clinical and commercial stage of own pipeline
- Continued royalty revenue stream from partnered pipelines
LCB's stratagies towards
the global Top
the global Top
Revolutionize the
platform that span
the entire ADC
spectrum
platform that span
the entire ADC
spectrum
Become a pioneer
with ADCs beyond
traditional cancer
therapy
with ADCs beyond
traditional cancer
therapy
Building LCB's own clinical stage pipeline
In-house pipeline growth
- Adding 1~2 in-house pipeline every year, securing 10 own pipeline by 2030
- Multiple co-development partnered pipeline through opt-in development
Transforming from early-stage licensing model to early-stage clinical development for significant value inflection
Revolutionize the platform that span the entire ADC spectrum
- Novel innovative ADC payloads that span multiple modes of action
- ADC in combination with small molecules for Immuno-Oncology to elicit highly focused immune recognition of tumors and induce highly potent and specific activity in multidrug-resistant tumor cells and induce cell death
- Continued improvement of new classes of linker and conjugation with differentiated advantages
Become a pioneer with ADCs beyond traditional cancer therapy
Revolutionary therapies that span the entire ADC spectrum ("Beyond Cytotoxic")
- Bispecific ADCs
- ADCs for Immunotherapy
- ADCs for infectous disease
- Combination therapy with antibodies and small molecules